Literature DB >> 17699395

Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease.

Vicente E Torres1, Bernard F King, Arlene B Chapman, Marijn E Brummer, Kyongtae T Bae, James F Glockner, Kraisthith Arya, Dana Risk, Joel P Felmlee, Jared J Grantham, Lisa M Guay-Woodford, William M Bennett, Saulo Klahr, Catherine M Meyers, Xiaoling Zhang, Paul A Thompson, J Philip Miller.   

Abstract

Whether changes in renal blood flow (RBF) are associated with and possibly contribute to cystic disease progression in autosomal dominant polycystic kidney disease (ADPKD) has not been ascertained. The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) was created to develop imaging techniques and analyses to evaluate progression. A total of 131 participants with early ADPKD had measurements of RBF and total kidney (TKV) and cyst (TCV) volumes by magnetic resonance and of GFR by iothalamate clearance at baseline and 1, 2, and 3 yr. The effects of age, gender, body mass index, hypertension status, mean arterial pressure (MAP), TKV, TCV, RBF, renal vascular resistance (RVR), GFR, serum uric acid, HDL and LDL cholesterol, 24-h urine volume, sodium (UNaE) and albumin (UAE) excretions, and estimated protein intake were examined at baseline on TKV, TCV, and GFR slopes. TKV and TCV increased, RBF decreased, and GFR remained stable. TKV, TCV, RVR, serum uric acid, UAE, UNaE, age, body mass index, MAP, and estimated protein intake were positively and RBF and GFR negatively correlated with TKV and TCV slopes. TKV, RBF, UNaE, and UAE were independent predictors of TKV and TCV slopes (structural disease progression). TKV, TCV, RVR, and MAP were negatively and RBF positively correlated with GFR slopes. Regression to the mean confounded the analysis of GFR slopes. TKV and RBF were independent predictors of GFR decline (functional disease progression). In ADPKD, RBF reduction (1) parallels TKV increase, (2) precedes GFR decline, and (3) predicts structural and functional disease progression.

Entities:  

Mesh:

Year:  2006        PMID: 17699395     DOI: 10.2215/CJN.00910306

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  58 in total

1.  Water prescription in autosomal dominant polycystic kidney disease: a pilot study.

Authors:  Connie J Wang; Catherine Creed; Franz T Winklhofer; Jared J Grantham
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

Review 2.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 3.  Diagnosis and management of childhood polycystic kidney disease.

Authors:  William E Sweeney; Ellis D Avner
Journal:  Pediatr Nephrol       Date:  2010-10-29       Impact factor: 3.714

4.  Patterns of Kidney Function Decline in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis From the HALT-PKD Trials.

Authors:  Godela M Brosnahan; Kaleab Z Abebe; Charity G Moore; Frederic F Rahbari-Oskoui; Kyongtae T Bae; Jared J Grantham; Robert W Schrier; William E Braun; Arlene B Chapman; Michael F Flessner; Peter C Harris; Marie C Hogan; Ronald D Perrone; Dana C Miskulin; Theodore I Steinman; Vicente E Torres
Journal:  Am J Kidney Dis       Date:  2018-01-03       Impact factor: 8.860

Review 5.  Rationale for early treatment of polycystic kidney disease.

Authors:  Jared J Grantham
Journal:  Pediatr Nephrol       Date:  2014-07-15       Impact factor: 3.714

6.  Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Michel Chonchol; Berenice Gitomer; Tamara Isakova; Xuan Cai; Isidro Salusky; Renata Pereira; Kaleab Abebe; Vicente Torres; Theodor I Steinman; Jared J Grantham; Arlene B Chapman; Robert W Schrier; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2017-07-13       Impact factor: 8.237

7.  Quantitative MRI of kidneys in renal disease.

Authors:  Timothy L Kline; Marie E Edwards; Ishan Garg; Maria V Irazabal; Panagiotis Korfiatis; Peter C Harris; Bernard F King; Vicente E Torres; Sudhakar K Venkatesh; Bradley J Erickson
Journal:  Abdom Radiol (NY)       Date:  2018-03

Review 8.  The importance of total kidney volume in evaluating progression of polycystic kidney disease.

Authors:  Jared J Grantham; Vicente E Torres
Journal:  Nat Rev Nephrol       Date:  2016-10-03       Impact factor: 28.314

9.  Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease.

Authors:  Imed Helal; Kim McFann; Berenice Reed; Xiang-Dong Yan; Robert W Schrier; Godela M Fick-Brosnahan
Journal:  Nephrol Dial Transplant       Date:  2012-12-04       Impact factor: 5.992

10.  Renal hemodynamic effects of the HMG-CoA reductase inhibitors in autosomal dominant polycystic kidney disease.

Authors:  Ladan Zand; Vicente E Torres; Timothy S Larson; Bernard F King; Sanjeev Sethi; Eric J Bergstralh; Andrea Angioi; Fernando C Fervenza
Journal:  Nephrol Dial Transplant       Date:  2015-11-27       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.